Taking a closer look at Primes GLP-1 Year-2 cost-of-care findings David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing research Last week, Prime Therapeutics (Prime) released the latest data from its ongoing real-world research on glucagon-like peptide-1 (GLP-1) agonist drugs, which showed individuals who newly started the drugs for weight loss experienced an average of $4,206 higher cost of care in their second year compared to like members not taking a GLP-1 drug for obesity
Studies indicate Thymosin Alpha-1 may aid in multiple aspects of anti-tumor immunity by: Enhanced T-cell activation As a result , T1 has been investigated as a complementary therapy in oncology settings, particularly where immune support is desirable
But here's the rub: if the dose is too low to be therapeutic, you might be wasting money on something that won't deliver real, sustained weight-loss benefits
It promotes long-term weight loss, and research suggests that ongoing treatment is required to maintain the reduced body weight
A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation
10.1093/annonc/mdu041 19 GreenM
